Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 289-295

  Orakzai, Sarwar H ^a   Nasir, Khurram ^b   Blaha, Michael ^c   Blumenthal, Roger S ^c   Raggi, Paolo ^d  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Coronary artery calcium; Lipoproteins; Non high density lipoprotein cholesterol

Indexed keywords

CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ELECTRON BEAM TOMOGRAPHY; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING TEST;

AGED; CALCINOSIS; CALCIUM; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES;

EID: 57749193318     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.014     Document Type: Article

References (27)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
2. Haffner S.M. Dyslipidemia management in adults with diabetes. Diabetes Care 27 Suppl. 1 (2004) S68-S71
3. Hsia S.H. Non-HDL cholesterol: into the spotlight. Diabetes Care 26 1 (2003) 240-242
4. Bittner V., Hardison R., Kelsey S.F., Weiner B.H., Jacobs A.K., and Spoko G. Bypass angioplasty revascularization investigation non-high-density lipoprotein cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI). Circulation 106 20 (2002) 2537-2542
5. Cui Y., Blumenthal R.S., Flaws J.A., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 11 (2001) 1413-1419
6. Nishizawa Y., Shoji T., Kakiya R., et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 84 (2003) S117-S120
7. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26 1 (2003) 16-23
8. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte Jr. M., and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15 4 (1990) 827-832
9. Raggi P., Callister T.Q., Cooil B., et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 101 8 (2000) 850-855
10. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C., and ACCESS Study Group. Atorvastatin comparative cholesterol efficacy and safety study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 3 (2001) 265-269
11. Lamarche B., Moorjani S., Lupien P.J., et al. B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 94 3 (1996) 273-278
12. Westerveld H.T., van Lennep J.E., van Lennep H.W., et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 18 7 (1998) 1101-1107
13. Frost P.H., and Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81 4A (1998) 26B-31B
14. Simon A., Chironi G., Gariepy J., Del Pino M., and Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 179 2 (2005) 339-344
15. Kawamoto R., Oka Y., Tomita H., and Kodama A. Non-HDL cholesterol as a predictor of carotid atherosclerosis in the elderly. J Atheroscler Thromb 12 3 (2005) 143-148
16. Stein J.H., and Rosenson R.H. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 157 11 (1997) 1170-1176
17. Wild S.H., Fortmann S.P., and Marcovina S.M. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 17 2 (1997) 239-245
18. Tatami R., Mabuchi H., Ueda K., et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64 6 (1981) 1174-1184
19. Krauss R.M., Lindgren F.T., Williams P.T., et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2 8550 (1987) 62-66
20. Hodis H.N., Mack W.J., Azen S.P., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90 1 (1994) 42-49
21. Vega G.L., and Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management?. Arteriosclerosis 10 5 (1990) 668-671
22. Abate N., Vega G.L., and Grundy S.M. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis 104 1-2 (1993) 159-171
23. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee. Circulation 60 2 (1979) 427-439
24. Havel R.J., and Rapaport E. Management of primary hyperlipidemia. N Engl J Med 332 22 (1995) 1491-1498
25. Geurian K., Pinson J.B., and Weart C.W. The triglyceride connection in atherosclerosis. Ann Pharmacother 26 9 (1992) 1109-1117
26. Austin M.A., King M.C., Vranizan K.M., and Kraus R.M. Atherogenic lipoprotein phenotype A proposed genetic marker for coronary heart disease risk. Circulation 82 2 (1990) 495-506
27. Orakzai S.H., Orakzai R.H., Nasir K., et al. Subclinical coronary atherosclerosis: racial profiling is necessary. Am Heart J 152 5 (2006) 819-827